Drug Profile
Siremadlin - Novartis Oncology
Alternative Names: HDM-201; NVP-HDM201Latest Information Update: 23 Feb 2024
Price :
$50
*
At a glance
- Originator Novartis
- Developer National Cancer Institute (France); Novartis; Novartis Oncology
- Class Antineoplastics; Chlorobenzenes; Imidazoles; Pyridines; Pyrimidines; Pyrroles; Small molecules
- Mechanism of Action Proto-oncogene protein c mdm2 inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase I/II Acute myeloid leukaemia; Liposarcoma; Myelofibrosis; Soft tissue sarcoma
- Phase I Colorectal cancer; Myelodysplastic syndromes
- No development reported Cancer; Haematological malignancies; Solid tumours; Uveal melanoma
Most Recent Events
- 05 Feb 2024 Novartis Pharmaceuticals terminates phase I/II clinical trials in Acute myeloid leukaemia (First-line therapy, Combination therapy) in Germany, Spain and Italy (PO) due to strategic decision from the sponsor (NCT05447663) (EudraCT2021-003596-34)
- 05 Feb 2024 Novartis Pharmaceuticals terminates phase I/II clinical trials in Acute myeloid leukaemia (First-line therapy, Monotherapy) in Germany, Spain and Italy (PO) due to strategic decision from the sponsor (NCT05447663) (EudraCT2021-003596-34)
- 26 Sep 2023 Siremadin is still in phase I trial for Myelodysplastic syndromes in Australia, Finland (PO)